Oppenheimer Maintains Outperform on Pliant Therapeutics, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has maintained an Outperform rating on Pliant Therapeutics (NASDAQ:PLRX) and increased the price target from $47 to $48.

May 07, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has maintained an Outperform rating on Pliant Therapeutics and raised the price target from $47 to $48.
The increase in price target by a reputable analyst like Jeff Jones from Oppenheimer is a strong positive signal for the stock. It suggests confidence in the company's future performance and potential for growth, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100